News : abstral

View:
 

Found press releases

 

Abstral® launches in Canada

6/14/2011 8:00 AM EST  -   Orexo
Uppsala, Sweden, June 14 2011 – Through its local partner, Orexo now initiates marketing and sales of the pain treatment Abstral in Canada.
In 2008, ProStrakan, who markets Abstral in Europe and the U.S., licensed its rights in the Canadian market to Paladin Labs Inc., which now launches the treatment of breakthrough pain in cancer patients in the Canadian market.
Paladin Labs is a specialty pharmaceutical...

Abstral® launched and now available in the United States

4/4/2011 8:15 AM EST  -   Orexo
Uppsala, April 4, 2011 - Orexo AB (STO: ORX) announces today that its partner ProStrakan Group plc (LSE: PSK) has launched Abstral in the United States.

Abstral, which is the only fast-acting sublingual tablet for the treatment of breakthrough cancer pain, is now available to patients in the US. In 2010 the market value for fast-acting fentanyl products was $530m. (Source: Wolter Kluwers). 

Abstral was...

Abstral® approved in Canada

2/22/2011 8:30 AM EST  -   Orexo
Uppsala, Sweden– February 22, 2010 – Orexo AB (STO: ORX) today announces that ProStrakan’s partner, Paladin Labs Inc. has been informed by Health Canada, the Canadian Government Department with responsibility for public health, that it has approved Abstral®.

Abstral is a rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl. The product is approved for the treatment of breakthrough pain in...

Orexo AB (publ.) - Year-end Report, January to December 2010

2/16/2011 2:00 AM EST  -   Orexo
Uppsala, February 16, 2011 - Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.
Key events during the period

· The loss after tax for the year excluding exceptional items...

Orexo and Invida jointly announce agreement for Abstral™ in Asia Pacific

1/14/2011 2:00 AM EST  -   Orexo
Alliance to Include Commercialization in 11 countries, including Australia and India
Uppsala, Sweden and Singapore – January 14, 2010 – Orexo AB (STO: ORX) and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia Pacific region for Abstral™, Orexo’s product for the treatment of breakthrough cancer pain. Under the terms of the agreement,...

FDA Approval for Abstral (Fentanyl) Sublingual Tablets - US launch planned for Q...

1/10/2011 2:00 AM EST  -   Orexo
Uppsala, January 10, 2011 - Orexo AB (STO: ORX) announces today that its partner ProStrakan Group plc (LSE: PSK) has received approval from the US Food and Drug Administration (FDA) for Abstral®. Abstral® is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain. “This...

Orexo announces new sales figures for Abstral™ from its partner ProStrakan and u...

11/16/2010 2:00 AM EST  -   Orexo
Uppsala, Sweden, November 16, 2010 - Orexo AB (STO: ORX) announces that its sales partner in the EU and USA for Abstral™, ProStrakan Group plc (“ProStrakan”) yesterday issued its interim report, which gave further information on progress with Abstral™, Orexo’s leading sublingual fentanyl product for treatment of breakthrough cancer pain. Abstral™ recorded sales of £14.1m (156 MSEK) in the first 10 months of the...

Orexo AB (publ.) – Interim report, January-September 2010

11/10/2010 2:00 AM EST  -   Orexo
Uppsala, November 10, 2010 - Abstral™ for treatment of breakthrough cancer pain continued to grow strongly
Key events during the period

· Net revenues amounted to MSEK 101.4 (208.2).
· Cash flow from operating activities as a negative MSEK 13.7 (neg:117.7)
· Royalties from Abstral™, Orexo’s leading sublingual fentanyl treatment for breakthrough cancer pain, increased to MSEK 30.3 (6.3)
· The loss...

Nomination Committee prior to Orexo’s Annual General Meeting 2011 and Financial ...

10/22/2010 10:00 AM EST  -   Orexo
Pursuant to the decision at the 2010 Annual General Meeting, the composition of the Nomination Committee for the 2011 Annual General Meeting is hereby announced. At Orexo’s Annual General Meeting on April 21, 2010, it was resolved that the company shall have a Nomination Committee consisting of representatives for the largest shareholders in terms of the number of votes and the chairman of the Board of...

Orexo announces that partner Kyowa Hakko Kirin is to conduct additional clinical...

8/27/2010 2:00 AM EST  -   Orexo
Uppsala, Sweden, August 27, 2010 – Orexo AB (STO: ORX) announces today that its partner Kyowa Hakko Kirin Co, Ltd. has decided to conduct additional clinical trials on the cancer pain drug KW-2246 (Orexo’s sublingual fentanyl product Abstral®).

An application for production and sale in Japan of KW-2246 as a treatment for breakthrough pain in cancer patients was made on February 24, 2010. However, following...